Pharmabiz4d
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...
pharmaphorum9y
Lilly awaits results for alternative amyloid drug in Alzheimer's
The data for LY3002813 will be the first test of the potential for antibodies as a passive immunisation against pyroglutamate- amyloid beta (pGlu-Abeta), a target that relates to but diverges from ...
The Pharma Letter6d
FTC clears BioArctic’s deal with BMS
Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...
pharmaphorum5d
AbbVie gets bigger in Alzheimer's R&D with Aliada takeover
The Boston biotech said the platform had enabled the development of ALIA-1758 – an anti-pyroglutamate amyloid beta (Aβ3pE) antibody, which it says is a 'potential best-in-class therapy for ...
Nature4y
Developing a new generation of Alzheimer’s disease treatments
Recent research has shown that the formation of highly synapto-/neurotoxic soluble Aβ oligomers is triggered by a specific form of Aβ called pyroglutamate-Aβ (pGlu-Aβ) 1. Probiodrug’s focus ...